COMMUNIQUÉS West-GlobeNewswire

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
14/08/2025
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO. “Tevogen is an [...]
Heald Launches First Money-Back Guarantee in Digital Diabetes Reversal
14/08/2025
Patients see measurable A1C improvement in 90-120 days or get a full refund ALPHARETTA, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Heald, a pioneering digital health company specializing in Type 2 diabetes reversal through [...]
Ligand Announces Closing of Convertible Senior Notes Offering
14/08/2025
JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.75% convertible [...]
Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress
14/08/2025
Conference call today, August 14, 2025, at 4:30 PM ET SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025. “We [...]
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
14/08/2025
Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ ® [...]
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
14/08/2025
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally comparable to [...]
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
14/08/2025
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued [...]
Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
14/08/2025
Reported statistically significant and clinically meaningful improvement in both primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial Hazard ratios and improvements in median progression- [...]
U.S. Oral Surgery Management Moves into 31st State
14/08/2025
Announces Four New Partner Practices IRVING, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial [...]
Press release: Transparency Notification from Shareholders
14/08/2025
Transparency Notification from Shareholders Ghent, Belgium – 14 August 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Tecan issues CHF 150 million straight bond
14/08/2025
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL [...]
Instinct Science Named to the 2025 Inc. 5000 List of Fastest-Growing Private Companies
14/08/2025
PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leading innovator in veterinary workflow, decision support, education, and practice management software, has been named to the Inc. 5000 list of the [...]
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
14/08/2025
Implemented cost reductions extend cash runway into first half of 2027 BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage [...]
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
14/08/2025
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
Stryker to participate in the 2025 Wells Fargo Securities Healthcare Conference
14/08/2025
Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor. Andy Pierce, Group [...]
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
14/08/2025
Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE [...]
Analytics For Life Completes Clinical Study of Non-Invasive Point-of-Care Test for Elevated Pulmonary Capillary Wedge Pressure (PCWP) Using Machine Learning
14/08/2025
Study achieves primary sensitivity endpoint, advancing diagnostics for heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH) Results build on data previously presented at ACC.25 in March [...]
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
14/08/2025
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of [...]
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
14/08/2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of [...]

Pages